#news #biotech Seres teams with cancer heavyweights for microbiome-checkpoint inhibitor combination trial

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Seres teams with cancer heavyweights for microbiome-checkpoint inhibitor combination trial .Seres Therapeutics has formed a collaboration to test microbiome therapy SER-401 in combination with an anti-PD-1 checkpoint inhibitor. The Parker Institute for Cancer Immunotherapy is sponsoring the trial, which will take place at the MD Anderson Cancer Center.

from FierceBiotech: Biotech http://ift.tt/2zBYQ7E